WAVE Life Sciences (WVE)
(Real Time Quote from BATS)
$6.10 USD
-0.10 (-1.61%)
Updated Jun 5, 2024 03:16 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for WAVE Life Sciences Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 113 | 4 | 41 | 20 | 16 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 113 | 4 | 41 | 20 | 16 |
Selling & Adminstrative & Depr. & Amort Expenses | 181 | 166 | 168 | 173 | 224 |
Income After Depreciation & Amortization | -68 | -163 | -127 | -153 | -208 |
Non-Operating Income | 10 | 2 | 5 | 3 | 15 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -58 | -161 | -122 | -151 | -194 |
Income Taxes | -1 | 1 | 0 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -58 | -162 | -122 | -150 | -194 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -58 | -162 | -122 | -150 | -194 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -59 | -153 | -117 | -143 | -201 |
Depreciation & Amortization (Cash Flow) | 9 | 10 | 10 | 10 | 8 |
Income After Depreciation & Amortization | -68 | -163 | -127 | -153 | -208 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 106.10 | 78.86 | 51.83 | 39.23 | 33.87 |
Diluted EPS Before Non-Recurring Items | -0.54 | -2.05 | -2.36 | -3.82 | -5.72 |
Diluted Net EPS (GAAP) | -0.54 | -2.05 | -2.36 | -3.82 | -5.72 |
Fiscal Year end for WAVE Life Sciences Ltd falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 12.54 | 29.06 | 49.21 | 22.11 | 12.93 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 12.54 | 29.06 | 49.21 | 22.11 | 12.93 |
SG&A, R&D, and Dept/Amort Expenses | 47.00 | 47.73 | 44.77 | 45.58 | 43.22 |
Income After SG&A, R&D, and Dept/Amort Expenses | -34.46 | -18.67 | 4.44 | -23.47 | -30.29 |
Non-Operating Income | 2.90 | 2.43 | 2.13 | 2.37 | 2.88 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -31.56 | -16.26 | 6.58 | -21.10 | -27.41 |
Income Taxes | 0.00 | 0.00 | -0.68 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -31.56 | -16.26 | 7.25 | -21.10 | -27.41 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -31.56 | -16.26 | 7.25 | -21.10 | -27.41 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 129.27 | 109.63 | 106.98 | 105.46 | 102.06 |
Diluted EPS Before Non-Recurring Items | -0.24 | -0.15 | 0.07 | -0.20 | -0.27 |
Diluted Net EPS (GAAP) | -0.24 | -0.14 | 0.07 | -0.20 | -0.27 |